Study of a new drug combination for stage III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of medications to keep stage III lung cancer from coming back after initial radiation and chemotherapy. It aims to see if this approach can help people live longer without their cancer returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your lung cancer must be stage III (locally advanced) and you must not have had any treatment for it yet, other than radiation and chemotherapy combined.
- After chemoradiation, your cancer must not have grown or spread.
- Your tumor must not have certain gene changes (like EGFR or ALK) that have other targeted treatments.
- You need to be in good enough health to carry out daily activities (performance status 0 or 1).
- You must be willing to provide blood, stool, and tumor tissue samples for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (chidamide and ivonescimab) for people with advanced non-small cell lung cancer that stopped responding to initial immunotherapy and has a specific protein marker (YAP) at high levels. It aims to see if this new combination can help when standard immunotherapy no longer works.
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
This trial tests a new combination of three medicines (two chemotherapies and an immunotherapy) for people with a certain type of advanced lung cancer called squamous non-small cell lung cancer. The goal is to see if this combo can help shrink or control the cancer better than current treatments.
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
This trial tests a combination of two medicines — a chemotherapy called irinotecan liposome and an immunotherapy called ivonescimab — for people whose small cell lung cancer has returned or progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.